dc.contributor
Institut Català de la Salut
dc.contributor
[Vivancos A] Grup de genòmica del Càncer, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Aranda E, Gómez-España MA] Department of Medical Oncology, Reina Sofía University Hospital, CIBERONC, Córdoba, Spain. [Benavides M] Department of Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Málaga, Spain. [Élez E] Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Toledano M] IMIBIC Instituto Maimonides Investigación Biomédica de Córdoba, Córdoba, Spain.
dc.contributor
Hospital Verge de la Cinta de Tortosa
dc.contributor.author
Vivancos Prellezo, Ana
dc.contributor.author
Benavides, Manuel
dc.contributor.author
Elez Fernandez, Mª Elena
dc.contributor.author
Gómez-España, Maria Auxiliadora
dc.contributor.author
Toledano, Marta
dc.contributor.author
Aranda Aguilar, Enrique
dc.date.accessioned
2025-10-25T05:37:30Z
dc.date.available
2025-10-25T05:37:30Z
dc.date.issued
2019-08-21T06:01:24Z
dc.date.issued
2019-08-21T06:01:24Z
dc.date.issued
2019-06-20
dc.identifier
Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, Toledano M, et al. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Sci Rep. 2019;9(1):8976.
dc.identifier
https://hdl.handle.net/11351/4265
dc.identifier
10.1038/s41598-019-45616-y
dc.identifier
WOS:000472137700072
dc.identifier.uri
http://hdl.handle.net/11351/4265
dc.description.abstract
Biopsy; KRAS mutation; Colorectal cancer
dc.description.abstract
Biòpsia; Mutació KRAS, Càncer colorectal
dc.description.abstract
Biopsia; Mutación KRAS, Cáncer colorrectal
dc.description.abstract
KRAS mutations are common in colorectal cancer (CRC). In this setting, mutation status determination in circulating-free DNA from blood samples (liquid biopsy) has been shown to be a viable alternative to tissue testing. The objective of this study was to compare the sensitivity of two liquid biopsy methods for detecting KRAS mutations in plasma samples from metastatic CRC patients. Samples with a positive (KRAS-MUT+) result and a mutant allelic fraction (MAF) < 5% according to the OncoBEAM RAS CRC assay were pairly analyzed by the Idylla ctKRAS Mutation Test (n = 116). In a cohort of 71 patients with at least 1 year of follow-up, the progression-free survival (PFS) was determined according to MAF values. Idylla detected KRAS mutations in 81/116 OncoBEAM KRAS-MUT+ samples with MAF < 5% and in 48/79 samples with MAF < 1%. Concordance between OncoBEAM and Idylla significantly improved at higher MAF values. PFS rates at 6 and 12 months tended to be lower in patients with MAF levels between 1% and 5% than in those with levels <1%. OncoBEAM demonstrated greater sensitivity for plasma detection of KRAS mutations than Idylla. Importantly, our data identified a "gray zone" below 1% MAF where Idylla showed reduced KRAS mutation detection, highlighting the importance of an accurate method to provide the mutational status of CRC patients.
dc.format
application/pdf
dc.publisher
Nature Research
dc.relation
Scientific Reports;9(1)
dc.relation
https://www.nature.com/articles/s41598-019-45616-y
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Còlon - Càncer - Diagnòstic
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
dc.subject
Other subheadings::Other subheadings::/diagnosis
dc.subject
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Hydrolases::Acid Anhydride Hydrolases::GTP Phosphohydrolases::GTP-Binding Proteins::Monomeric GTP-Binding Proteins::ras Proteins::Proto-Oncogene Proteins p21(ras)
dc.subject
Other subheadings::Other subheadings::Other subheadings::/genetics
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Liquid Biopsy
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
dc.subject
Otros calificadores::Otros calificadores::/diagnóstico
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::hidrolasas::ácido anhídrido hidrolasas::GTP fosfohidrolasas::proteínas de unión al GTP::proteínas de unión al GTP monoméricas::proteínas ras::proteínas protooncogénicas p21(ras)
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/genética
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::biopsia líquida
dc.title
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
